Is REDX or APTA more profitable?

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redx Pharma N/A -180.80% -43.95% Aptamer Group -178.52% -135.35% -44.96%

Do analysts recommend HVO or APTA?

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 102.70%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Aptamer Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Aptamer Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, HVO or APTA?

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.09 £17.84M -£0.87 N/A Aptamer Group £1.38M 11.58 -£14.17M -£0.11 N/A

Is HVO or APTA more profitable?

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Aptamer Group -178.52% -135.35% -44.96%

Aptamer Group (APTA) Competitors

GBX 0.46 -0.01 (-2.74%)

As of 07/31/2026 12:00 PM Eastern

Compare

APTA vs. REDX, ETX, HVO, HEMO, and COIL

Should you buy Aptamer Group stock or one of its competitors? MarketBeat compares Aptamer Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptamer Group include Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), and Roquefort Therapeutics (COIL). These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to Redx Pharma?

Redx Pharma (LON:REDX) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redx Pharma	N/A	-180.80%	-43.95%
Aptamer Group	-178.52%	-135.35%	-44.96%

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Redx Pharma	Neutral
Aptamer Group	Neutral

72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.902, meaning that its stock price is 10% less volatile than the broader market.

Aptamer Group has lower revenue, but higher earnings than Redx Pharma. Aptamer Group is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A
Aptamer Group	£1.38M	11.58	-£14.17M	-£0.11	N/A

Summary

Redx Pharma beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to e-therapeutics?

e-therapeutics (LON:ETX) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
e-therapeutics	Neutral
Aptamer Group	Neutral

e-therapeutics has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. e-therapeutics' return on equity of -38.75% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
e-therapeutics	N/A	-38.75%	-29.10%
Aptamer Group	-178.52%	-135.35%	-44.96%

26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.902, indicating that its share price is 10% less volatile than the broader market.

e-therapeutics has higher earnings, but lower revenue than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A
Aptamer Group	£1.38M	11.58	-£14.17M	-£0.11	N/A

Summary

e-therapeutics beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to hVIVO?

hVIVO (LON:HVO) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Aptamer Group	Neutral

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Aptamer Group	-178.52%	-135.35%	-44.96%

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.09	£17.84M	-£0.87	N/A
Aptamer Group	£1.38M	11.58	-£14.17M	-£0.11	N/A

hVIVO has a beta of 1.707, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.902, indicating that its stock price is 10% less volatile than the broader market.

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 102.70%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Aptamer Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aptamer Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.8% of hVIVO shares are held by institutional investors. Comparatively, 3.0% of Aptamer Group shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 7.3% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

hVIVO beats Aptamer Group on 10 of the 14 factors compared between the two stocks.

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Aptamer Group (LON:APTA) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	11.58	-£14.17M	-£0.11	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

Aptamer Group has a beta of 0.902, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
Hemogenyx Pharmaceuticals	Neutral

Summary

Hemogenyx Pharmaceuticals beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.902, suggesting that its share price is 10% less volatile than the broader market.

Roquefort Therapeutics has higher earnings, but lower revenue than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
Aptamer Group	£1.38M	11.58	-£14.17M	-£0.11	N/A

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Roquefort Therapeutics	Neutral
Aptamer Group	Neutral

2.1% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 36.1% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Aptamer Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aptamer Group has a net margin of -178.52% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
Aptamer Group	-178.52%	-135.35%	-44.96%

Summary

Roquefort Therapeutics and Aptamer Group tied by winning 5 of the 10 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APTA vs. The Competition

Export

Metric	Aptamer Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.41M	£3.54B	£7.16B	£2.79B
Dividend Yield	N/A	3.78%	2.59%	6.15%
P/E Ratio	-4.20	7.38	282.25	368.29
Price / Sales	11.58	1,273.79	591.88	83,501.30
Price / Cash	N/A	44.80	28.60	27.89
Price / Book	2.16	16.78	10.93	7.04
Net Income	-£14.17M	-£12.56M	£3.50B	£5.89B
7 Day Performance	-4.35%	-1.82%	-0.64%	6.05%
1 Month Performance	-1.70%	-8.45%	-3.78%	-0.22%
1 Year Performance	29.05%	48.33%	61.99%	63.72%

Aptamer Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APTA Aptamer Group	N/A	GBX 0.46 -2.7%	N/A	+29.1%	£16.41M	£1.38M	N/A	37	Gap Up
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
HVO hVIVO	N/A	GBX 7.06 -2.0%	GBX 15 +112.6%	-26.0%	£48.57M	£46.77M	N/A	N/A
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 685.11 -8.4%	N/A	+296.2%	£46.59M	N/A	N/A	14	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptamer Group (APTA) Competitors

APTA vs. REDX, ETX, HVO, HEMO, and COIL

How does Aptamer Group compare to Redx Pharma?

Summary

How does Aptamer Group compare to e-therapeutics?

Summary

How does Aptamer Group compare to hVIVO?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptamer Group (APTA) Competitors

APTA vs. REDX, ETX, HVO, HEMO, and COIL

How does Aptamer Group compare to Redx Pharma?

Is REDX or APTA more profitable?

Does the media favor REDX or APTA?

Do institutionals and insiders have more ownership in REDX or APTA?

Which has more risk & volatility, REDX or APTA?

Which has stronger valuation & earnings, REDX or APTA?

Summary

How does Aptamer Group compare to e-therapeutics?

Does the media prefer ETX or APTA?

Is ETX or APTA more profitable?

Do insiders and institutionals hold more shares of ETX or APTA?

Which has more volatility and risk, ETX or APTA?

Which has preferable valuation & earnings, ETX or APTA?

Summary

How does Aptamer Group compare to hVIVO?

Does the media prefer HVO or APTA?

Is HVO or APTA more profitable?

Which has higher valuation and earnings, HVO or APTA?

Which has more volatility and risk, HVO or APTA?

Do analysts recommend HVO or APTA?

Do institutionals & insiders hold more shares of HVO or APTA?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Is APTA or HEMO more profitable?

Do insiders and institutionals hold more shares of APTA or HEMO?

Which has stronger earnings & valuation, APTA or HEMO?

Which has more volatility and risk, APTA or HEMO?

Does the media prefer APTA or HEMO?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Which has more volatility & risk, COIL or APTA?

Which has higher valuation & earnings, COIL or APTA?

Does the media refer more to COIL or APTA?

Do insiders and institutionals hold more shares of COIL or APTA?

Is COIL or APTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools